AU2015350315B2 - Aminopyrazine compounds with A2A antagonist properties - Google Patents
Aminopyrazine compounds with A2A antagonist properties Download PDFInfo
- Publication number
- AU2015350315B2 AU2015350315B2 AU2015350315A AU2015350315A AU2015350315B2 AU 2015350315 B2 AU2015350315 B2 AU 2015350315B2 AU 2015350315 A AU2015350315 A AU 2015350315A AU 2015350315 A AU2015350315 A AU 2015350315A AU 2015350315 B2 AU2015350315 B2 AU 2015350315B2
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- amino
- pyrazine
- oxazol
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 Cc1nc(*)c(*)[o]1 Chemical compound Cc1nc(*)c(*)[o]1 0.000 description 7
- NDHOGRFNBCDDMH-UHFFFAOYSA-N CC(C1)C(C)=C(C)OC1c1c(C)nc(C(O)=O)c(N)n1 Chemical compound CC(C1)C(C)=C(C)OC1c1c(C)nc(C(O)=O)c(N)n1 NDHOGRFNBCDDMH-UHFFFAOYSA-N 0.000 description 1
- AOTYXXRNAAMGGS-DMGVMHNSSA-N CC/C(/C)=C(/C(/C(OCC)=O)=N\C(\C)=C(/C)\C1=CC(C)CC=CO1)\N Chemical compound CC/C(/C)=C(/C(/C(OCC)=O)=N\C(\C)=C(/C)\C1=CC(C)CC=CO1)\N AOTYXXRNAAMGGS-DMGVMHNSSA-N 0.000 description 1
- ILUAZXSAAIWAJF-UHFFFAOYSA-N CCCOC(CN)SCC Chemical compound CCCOC(CN)SCC ILUAZXSAAIWAJF-UHFFFAOYSA-N 0.000 description 1
- DXCJMEHIKVMYTK-UHFFFAOYSA-N CCc1c(-c2c(C)c(CC)c(C(O)=O)c(N)n2)[o]cc1 Chemical compound CCc1c(-c2c(C)c(CC)c(C(O)=O)c(N)n2)[o]cc1 DXCJMEHIKVMYTK-UHFFFAOYSA-N 0.000 description 1
- QAYZLHYSDXJKNY-UHFFFAOYSA-N CCc1nccnc1C=O Chemical compound CCc1nccnc1C=O QAYZLHYSDXJKNY-UHFFFAOYSA-N 0.000 description 1
- QNLAYSBIWHHNIT-UHFFFAOYSA-N Cc1cccnc1CN Chemical compound Cc1cccnc1CN QNLAYSBIWHHNIT-UHFFFAOYSA-N 0.000 description 1
- SGSZFTVNOSOSQE-UHFFFAOYSA-N Cc1cnc(CN)nc1 Chemical compound Cc1cnc(CN)nc1 SGSZFTVNOSOSQE-UHFFFAOYSA-N 0.000 description 1
- XGDYXMGROZBQIU-UHFFFAOYSA-N NCc1ncccc1C1CC1 Chemical compound NCc1ncccc1C1CC1 XGDYXMGROZBQIU-UHFFFAOYSA-N 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-M O=C1[N-]C=CC=C1 Chemical compound O=C1[N-]C=CC=C1 UBQKCCHYAOITMY-UHFFFAOYSA-M 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N Oc1ncccc1 Chemical compound Oc1ncccc1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081262P | 2014-11-18 | 2014-11-18 | |
| US62/081,262 | 2014-11-18 | ||
| PCT/US2015/060509 WO2016081290A1 (en) | 2014-11-18 | 2015-11-13 | Aminopyrazine compounds with a2a antagonist properties |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015350315A1 AU2015350315A1 (en) | 2017-05-18 |
| AU2015350315B2 true AU2015350315B2 (en) | 2020-06-25 |
Family
ID=56014406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015350315A Ceased AU2015350315B2 (en) | 2014-11-18 | 2015-11-13 | Aminopyrazine compounds with A2A antagonist properties |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10472347B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3220910B1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP6779204B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20170083136A (cg-RX-API-DMAC10.html) |
| CN (1) | CN107106558A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2015350315B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112017010261A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2967944C (cg-RX-API-DMAC10.html) |
| MX (1) | MX381180B (cg-RX-API-DMAC10.html) |
| RU (1) | RU2727805C2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016081290A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311645B2 (en) * | 2016-07-12 | 2025-11-01 | Revolution Medicines Inc | 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CN108570054B (zh) * | 2017-03-07 | 2021-07-16 | 广州再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| JP2020527588A (ja) * | 2017-07-18 | 2020-09-10 | ニューベイション・バイオ・インコーポレイテッドＮｕｖａｔｉｏｎ Ｂｉｏ Ｉｎｃ． | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
| JP2020532541A (ja) | 2017-08-31 | 2020-11-12 | コーバス・ファーマシューティカルズ・インコーポレイテッド | アデノシンａ２ｂ受容体およびアデノシンａ２ａ受容体を調節するための化合物および方法 |
| BR112020007058A2 (pt) | 2017-10-12 | 2020-10-06 | Revolution Medicines, Inc. | compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos |
| US11498923B2 (en) | 2017-12-13 | 2022-11-15 | Merck Sharp & Dohme Llc | Substituted imidazo[1,2-c]quinazolines as A2A antagonists |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| SG11202101486RA (en) | 2018-08-16 | 2021-03-30 | Innate Tumor Immunity Inc | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| US20200079793A1 (en) * | 2018-08-31 | 2020-03-12 | Corvus Pharmaceuticals, Inc. | Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor |
| JP2022507734A (ja) | 2018-11-20 | 2022-01-18 | メルク・シャープ・アンド・ドーム・コーポレーション | 置換アミノトリアゾロピリミジン及びアミノトリアゾロピラジンアデノシン受容体アンタゴニスト、医薬組成物及びそれらの使用 |
| US12414952B2 (en) | 2018-11-20 | 2025-09-16 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| JP2022511778A (ja) | 2018-11-30 | 2022-02-01 | メルク・シャープ・アンド・ドーム・コーポレーション | アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用 |
| AR117164A1 (es) | 2018-11-30 | 2021-07-14 | Merck Sharp & Dohme | Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer |
| WO2020146795A1 (en) | 2019-01-11 | 2020-07-16 | Omeros Corporation | Methods and compositions for treating cancer |
| WO2020150674A1 (en) | 2019-01-18 | 2020-07-23 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
| US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
| TW202128650A (zh) * | 2019-10-11 | 2021-08-01 | 德商拜耳動物保健有限公司 | 作為殺蟲劑之新穎的雜芳基取代之吡𠯤衍生物 |
| CN111285798A (zh) * | 2020-04-09 | 2020-06-16 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺盐酸盐的合成方法 |
| CN111423364A (zh) * | 2020-05-19 | 2020-07-17 | 阿里生物新材料（常州）有限公司 | 一种（3-环丙基吡啶-2-基）甲胺的合成方法 |
| EP3929189A1 (en) * | 2020-06-25 | 2021-12-29 | Bayer Animal Health GmbH | Novel heteroaryl-substituted pyrazine derivatives as pesticides |
| AU2022241754A1 (en) | 2021-03-23 | 2023-10-19 | BioAge Labs, Inc. | Inhibitors of nlrp3 inflammasome |
| CN117157278A (zh) * | 2021-03-23 | 2023-12-01 | 柏奥艾奇实验室公司 | Nlrp3炎性体的抑制剂 |
| EP4469460A1 (en) | 2022-01-28 | 2024-12-04 | Bioage Labs, Inc. | N-oxide inhibitors of nlrp3 inflammasome |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| US12516018B2 (en) * | 2023-03-30 | 2026-01-06 | Brandeis University | Solid-solid phase change aromatic azo compounds, method of manufacture, and use for thermal energy storage and release |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025207644A1 (en) | 2024-03-26 | 2025-10-02 | BioAge Labs, Inc. | Inhibitors of nlrp3 inflammasome |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
| US5565460A (en) | 1993-07-27 | 1996-10-15 | Kyowa Hakko Koygo Co., Ltd. | Therapeutic purine agents for parkinson's disease |
| IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
| IT1291372B1 (it) | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| PT1283839E (pt) | 2000-05-26 | 2005-08-31 | Schering Corp | Antagonistas do receptor a2a da adenosina |
| SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| EP1641779A1 (en) * | 2003-06-18 | 2006-04-05 | AstraZeneca AB | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
| CA2543644A1 (en) | 2003-10-27 | 2005-05-06 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| US20060199828A1 (en) * | 2005-03-04 | 2006-09-07 | Georg Jaeschke | Pyrazine-2-carboxyamide derivatives |
| ES2270715B1 (es) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| WO2010141275A1 (en) * | 2009-06-01 | 2010-12-09 | Merck Sharp & Dohme Corp. | Pyrazine carboxamide orexin receptor antagonists |
-
2015
- 2015-11-13 AU AU2015350315A patent/AU2015350315B2/en not_active Ceased
- 2015-11-13 JP JP2017526527A patent/JP6779204B2/ja not_active Expired - Fee Related
- 2015-11-13 EP EP15861650.8A patent/EP3220910B1/en active Active
- 2015-11-13 US US15/525,788 patent/US10472347B2/en active Active
- 2015-11-13 CA CA2967944A patent/CA2967944C/en not_active Expired - Fee Related
- 2015-11-13 BR BR112017010261-7A patent/BR112017010261A2/pt not_active IP Right Cessation
- 2015-11-13 RU RU2017120853A patent/RU2727805C2/ru active
- 2015-11-13 KR KR1020177016281A patent/KR20170083136A/ko not_active Withdrawn
- 2015-11-13 MX MX2017006483A patent/MX381180B/es unknown
- 2015-11-13 WO PCT/US2015/060509 patent/WO2016081290A1/en not_active Ceased
- 2015-11-13 CN CN201580073488.3A patent/CN107106558A/zh active Pending
-
2020
- 2020-08-19 JP JP2020138418A patent/JP2020193211A/ja not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| BONNEFOUS C ET AL, "Dipyridyl amides: potent metabotropic glutamate subtype 5 (mGlu5) receptor antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 15, no. 4,, pages 1197 - 1200 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US10472347B2 (en) | 2019-11-12 |
| WO2016081290A1 (en) | 2016-05-26 |
| BR112017010261A2 (pt) | 2018-02-06 |
| RU2727805C2 (ru) | 2020-07-24 |
| CA2967944A1 (en) | 2016-05-26 |
| EP3220910A4 (en) | 2018-04-25 |
| CN107106558A (zh) | 2017-08-29 |
| MX381180B (es) | 2025-03-12 |
| CA2967944C (en) | 2020-11-17 |
| EP3220910B1 (en) | 2020-01-15 |
| RU2017120853A (ru) | 2018-12-19 |
| JP2020193211A (ja) | 2020-12-03 |
| MX2017006483A (es) | 2017-09-12 |
| RU2017120853A3 (cg-RX-API-DMAC10.html) | 2019-06-17 |
| EP3220910A1 (en) | 2017-09-27 |
| AU2015350315A1 (en) | 2017-05-18 |
| KR20170083136A (ko) | 2017-07-17 |
| JP2017533946A (ja) | 2017-11-16 |
| US20180327385A1 (en) | 2018-11-15 |
| JP6779204B2 (ja) | 2020-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3220910B1 (en) | Aminopyrazine compounds with a2a antagonist properties | |
| AU2014338549B2 (en) | Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors | |
| EP3253390B1 (en) | Aminoquinazoline compounds as a2a antagonist | |
| EP2424859B1 (en) | Inhibitors of pi3 kinase and / or mtor | |
| JP2018150358A (ja) | Ｔａｎｋ結合キナーゼインヒビター化合物 | |
| EP2970313B1 (en) | Substituted 7-azabicycles and their use as orexin receptor modulators | |
| EP3331532B1 (en) | Substituted aminoquinazoline compounds as a2a antagonist | |
| EP3883575B1 (en) | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use | |
| EP3307067B1 (en) | Aminopyrazine compounds with a2a antagonist properties | |
| WO2019002606A1 (en) | ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS | |
| WO2013142269A1 (en) | Imidazotriazinone compounds | |
| WO2013012500A1 (en) | Trpv4 antagonists | |
| CN115181092B (zh) | 吡嗪化合物和其用途 | |
| TW202506660A (zh) | Mrgprx2拮抗劑及其使用方法 | |
| US20250171447A1 (en) | Adenosine receptor antagonists, pharmaceutical compositions and their use thereof | |
| HK1222388B (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |